Michele Spina

Prognostic Scoring System for Primary CNS Lymphomas: The International Extranodal Lymphoma Study Group Experience

Andrés J.M. Ferreri, Jean‐Yves Blay, Michele Reni et al. · Journal of Clinical Oncology · 2003 · 824 citations

Randomized Phase III Trial of High–Dose-Intensity Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (MVAC) Chemotherapy and Recombinant Human Granulocyte Colony-Stimulating Factor Versus Classic MVAC in Advanced Urothelial Tract Tumors: European Organization for Research and Treatment of Cancer Protocol No. 30924

Cora N. Sternberg, P.H.M. de Mulder, Jan H. Schornagel et al. · Journal of Clinical Oncology · 2001 · 624 citations

Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial

H. Miles Prince, Youn H. Kim, Reinhard Dummer et al. · The Lancet · 2017 · 569 citations

Hematological Malignancy, Lymphoid Neoplasia, Medicine +9

Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours

Cora N. Sternberg, PHM de Mulder, Jan H. Schornagel et al. · European Journal of Cancer · 2005 · 542 citations

Year Update, Urology, Surgical Oncology +5

A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study

Jesse J. Swen, Cathelijne H. van der Wouden, Lisanne E. N. Manson et al. · The Lancet · 2023 · 462 citations · Full text

Drug Safety, Adverse Drug Reactions, Pharmacoepidemiology +9